Dose-dense chemotherapy in advanced ovarian cancer
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference13 articles.
1. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial;Katsumata;Lancet,2009
2. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du Bois;Ann Oncol,2005
3. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma;Vasey;J Natl Cancer Inst,2004
4. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup;Bookman;J Clin Oncol,2009
5. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion;Eisenhauer;J Clin Oncol,1994
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3‐induced dormant ovarian cancer xenografts;Cancer;2019-01-08
2. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial;Journal of the Egyptian National Cancer Institute;2014-09
3. Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib);Molecular Cancer Therapeutics;2014-06-30
4. Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer;Molecular Pharmaceutics;2013-08-21
5. Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer;Expert Opinion on Pharmacotherapy;2013-08-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3